Skip to main content

Company

GSK PLC

LON:GSK

GSK PLC will be a fully focused biopharma company following the demerger of its world-leading consumer healthcare business, Haleon, in July 2022. The company will prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease.

749 stories · page 1 of 8

GSK's cancer pipeline undervalued, says Jefferies after science chief chat

By Ian Lyall 3d

GSK strikes deal worth up to $750 million for cancer drug

By Ian Lyall 15/09

GSK drug cuts death risk by 54% in small cell lung cancer trial

By Ian Lyall 14/09

Microsoft, Dell, Palo Alto and Broadcom: analyst calls of the week

By Angela Harmantas 04/09

GSK's mRNA flu vaccine data closely tracks Moderna's, Deutsche Bank says

By Ian Lyall 04/09

Panmure and Cavendish reiterate buy on Hutchmed after GSK deal

By Ian Lyall 03/09

GSK shares kept at neutral by Citi as unproven phase III pipeline curbs long-term growth

By Ian Lyall 20/08

GSK hits three-month high as vaccines help earnings top forecasts

By Oliver Haill 28/07

Biotech's takeover boom may be running out of buyers

By Ian Lyall 22/07

Jefferies resumes GSK coverage at 'buy', sees 30% upside on oncology firepower

By Ian Lyall 17/07

UBS keeps GSK at 'neutral' with focus on chief executive's strategy update

By Ian Lyall 13/07

GSK's Nuvalent deal tackles HIV cliff to win cautious backing from analysts

By Oliver Haill 10/06

GSK falls as £8bn takeover of Nuvalent is largest deal in a decade

By Oliver Haill 09/06

US bank sees GSK oncology pipeline as major value driver after New York conference

By Ian Lyall 04/06

UBS says UK stocks are better supported but not broadly so, as earnings lead while sentiment drags

By Ian Lyall 03/06

Pharma & Biotech

GSK hepatitis B drug a long-term opportunity but US bank holds back from upgrading

By Proactive 29/05

Pharma & Biotech

JP Morgan retains 'underweight' on GSK with £17 price target as earnings upgrade potential seen as limited

By Proactive 30/04

Pharma & Biotech

GSK reaffirms 2026 guidance after strong first-quarter performance

By Proactive 29/04

Pharma & Biotech

GSK unit wins partial dismissal in dostarlimab licence dispute with AnaptysBio

By Proactive 27/04

Pharma & Biotech

Broker reiterates GSK 'buy' as court ruling lifts vaccine cloud

By Proactive 25/03

Pharma & Biotech

GSK sells rights to rare liver disease drug for up to $690m

By Proactive 09/03

Pharma & Biotech

GSK pays $950m for a pulmonary hypertension drug designed to avoid the bleeding risk that limits rival treatments

By Proactive 25/02

Pharma & Biotech

Citi lifts GSK target price but keeps neutral stance after rally

By Proactive 09/02

Pharma & Biotech

ShoreCap says GSK has cracked it and the £40bn prize is now in sight

By Proactive 06/02

Pharma & Biotech

GSK beat the numbers, but the real story was the guidance

By Proactive 04/02

Pharma & Biotech

GSK delivers solid 2025 results, reaffirms growth outlook for 2026

By Proactive 04/02

Pharma & Biotech

GSK snaps up food allergy drug specialist RAPT for $2.2bn

By Proactive 20/01

Pharma & Biotech

GSK reports breakthrough trial results for hepatitis B drug

By Proactive 07/01

Pharma & Biotech

GSK's asthma treatment gets greenlight in Japan

By Proactive 06/01

Pharma & Biotech

GSK is next to agree drug pricing deal with US government

By Proactive 22/12/2025

Pharma & Biotech

GSK drug for aggressive lung cancer wins US orphan status

By Proactive 10/12/2025

Pharma & Biotech

GSK unit sues AnaptysBio in row over Jemperli rights

By Proactive 21/11/2025

Pharma & Biotech

GSK’s shares stuck in the middle lane

By Proactive 04/11/2025

Pharma & Biotech

GSK delivers one of its cleaner beats, says leading bank

By Proactive 30/10/2025

Pharma & Biotech

GSK raises its sights after strong quarter and upgraded outlook

By Proactive 29/10/2025

Pharma & Biotech

GSK lifts profit outlook after strong quarter and upbeat broker reaction

By Proactive 29/10/2025

Pharma & Biotech

GSK hikes outlook as sales and earning grow faster than expected

By Proactive 29/10/2025

Pharma & Biotech

GSK cancer drug wins EU orphan status for small-cell lung cancer

By Proactive 28/10/2025

Pharma & Biotech

GSK chief exec Emma Walmsley to step down at end of December

By Proactive 29/09/2025

Archive

FTSE 100 Live: London miners and GSK drive gains, but oil price retreats from highs

By Proactive 29/09/2025

Pharma & Biotech

GSK commits $30bn to US drug research and manufacturing

By Proactive 17/09/2025

Pharma & Biotech

GSK opens higher after priority review for new gonorrhoea pill

By Proactive 11/08/2025

Pharma & Biotech

GSK secures $370 million settlement and future royalties in CureVac mRNA patent dispute

By Proactive 08/08/2025

Pharma & Biotech

GSK may have numbers may have been flattered by order timing, says bank

By Proactive 30/07/2025

Pharma & Biotech

GSK confident of hitting top end of 2025 targets after strong second quarter

By Proactive 30/07/2025

Pharma & Biotech

GSK shares rise on $500m drug deal with China’s Hengrui

By Proactive 28/07/2025

Pharma & Biotech

GSK to make $500m down payment on Chinese licensing deal worth up to $12bn

By Proactive 28/07/2025

Pharma & Biotech

GSK shares analysts get out the red pens after FDA knock-back wipes £3bn from drug maker's value

By Proactive 18/07/2025

Pharma & Biotech

GSK shares slide 6% after US panel rejects key cancer drug combination

By Proactive 18/07/2025

Pharma & Biotech

GSK gets red light from FDA cancer committee on Blenrep combos

By Proactive 18/07/2025

Pharma & Biotech

GSK counts on Blenrep rebound to drive £40bn sales goal

By Proactive 03/07/2025

Pharma & Biotech

GSK seeks broader European approval for RSV vaccine

By Proactive 13/06/2025

Pharma & Biotech

GSK splashes out $1.2bn up-front for liver treatment still in clinical trials

By Proactive 14/05/2025

Pharma & Biotech

GSK jumps 4% as earnings beat boosts confidence

By Proactive 30/04/2025

Pharma & Biotech

GSK: Disproportionately discounted, but earnings beat shows signs of reappraisal

By Proactive 30/04/2025

Pharma & Biotech

GSK beats earnings forecasts despite weaker vaccine sales

By Proactive 30/04/2025

Archive

FTSE 100 lifted by GSK and defensive stocks as markets wobble on US GDP surprise

By Proactive 30/04/2025

Pharma & Biotech

GSK update brings US vaccine exposure into spotlight, as sceptic RFK Jr looms

By Proactive 25/04/2025

Archive

FIVE at FIVE: US tariffs kick in, China kicks back, pharma plunges, US tech warning, JD jumps

By Proactive 09/04/2025

Pharma & Biotech

UK pharma escapes worst of Trump tariffs (for now) but uncertainty may keep pressure on shares

By Proactive 03/04/2025

Pharma & Biotech

GSK meningitis jab gets green light from US FDA

By Proactive 17/02/2025

Pharma & Biotech

GSK's speciality medicines arm gets the seal of approval from UK broker

By Proactive 12/02/2025

Pharma & Biotech

GSK prelims get City thumbs up as investment banks upgrade

By Proactive 06/02/2025

Pharma & Biotech

GSK shares rise 5% as it navigates vaccines woes to upgrade sales target

By Proactive 05/02/2025

Pharma & Biotech

GSK upgrades long-term sales target; but Arexvy's struggles are confirmed

By Proactive 05/02/2025

Pharma & Biotech

GSK to explore cancer vaccines with Oxford University in £50mln deal

By Proactive 27/01/2025

Pharma & Biotech

GSK swoops for US cancer specialist in $1.15bn deal

By Proactive 13/01/2025

Pharma & Biotech

GSK's new shingles jab submitted for review by US regulator

By Proactive 10/01/2025

Pharma & Biotech

GSK swooping to buy US biotech IDRx for $1bn - report

By Proactive 08/01/2025

Pharma & Biotech

GSK’s experimental cancer drug wins receives support from US regulator

By Proactive 07/01/2025

Pharma & Biotech

GSK’s Nucala approved in China for treating nasal polyps

By Proactive 03/01/2025

Pharma & Biotech

GSK’s FIRST trial achieves progression-free survival milestone in advanced ovarian cancer

By Proactive 20/12/2024

Pharma & Biotech

GSK passes three significant milestones with new cancer drug given a double boost

By Proactive 16/12/2024

Pharma & Biotech

GSK says blood cancer drug shows dramatic survival gains in key trial

By Proactive 09/12/2024

Pharma & Biotech

GSK extends vaccine partnership with Zhifei in China

By Proactive 05/12/2024

Pharma & Biotech

GSK’s receives European Commission green light for liquid form of key vaccine

By Proactive 27/11/2024

Pharma & Biotech

GSK submits multiple myeloma treatment for approval to the US regulator

By Proactive 25/11/2024

Pharma & Biotech

GSK’s RSV vaccine gets greenlight in Japan

By Proactive 22/11/2024

Pharma & Biotech

GSK trial shows promising results for treatment of persistent itch in rare liver disease

By Proactive 19/11/2024

Pharma & Biotech

FIVE at FIVE: GSK, AstraZeneca plummet; LandSec profits; Economy stalls; FTSE 100 meanders; TT snubs Volex

By Proactive 15/11/2024

Pharma & Biotech

Trump anti-vax health appointment wipes £7bn from AstraZeneca and GSK

By Proactive 15/11/2024

Pharma & Biotech

GSK going nowhere while key vaccines struggle, says US bank

By Proactive 12/11/2024

Pharma & Biotech

GSK falls 3% as vaccines disappoint (again)

By Proactive 30/10/2024

Pharma & Biotech

GSK looking to move on from Zantac litigation

By Proactive 25/10/2024

Pharma & Biotech

GSK has earnings estimate cut, slow shingles vaccine uptake cited

By Proactive 21/10/2024

Pharma & Biotech

GSK hails phase III nasal polyps success

By Proactive 14/10/2024

FIVE at FIVE: GSK settles; Tesla Robotaxi launch; Ryanair slashes German flights; Indivior plunges; FTSE 100 dips

By Proactive 10/10/2024

Pharma & Biotech

GSK Zantac settlement a 'clear win', say brokers

By Proactive 10/10/2024

Pharma & Biotech

GSK settles US Zantac lawsuit for $2.2bn

By Proactive 10/10/2024

Archive

FTSE 100 struggles for direction; US inflation ahead of expectations

The FTSE 100 gave up earlier gains to trade below the mark on Thursday

By Proactive 10/10/2024

Pharma & Biotech

Does GSK's RSV jab work too well?

By Proactive 01/10/2024

Pharma & Biotech

GSK cancer drugs fast-tracked by Chinese

By Proactive 13/09/2024

Pharma & Biotech

GSK enjoys success with mRNA flu vaccine trial

By Proactive 12/09/2024

Pharma & Biotech

GSK 'clouds' blowing over suggests Berenberg

By Proactive 11/09/2024

Pharma & Biotech

GSK herpes vaccine fails in clinical trial

By Proactive 11/09/2024

Pharma & Biotech

GSK drug promotes ‘significant and clinically meaningful reduction’ in asthma symptoms

By Proactive 09/09/2024

Pharma & Biotech

GSK sees positive COPD trial results

By Proactive 06/09/2024

Pharma & Biotech

GSK: European Union approves label expansion for RSV jab

By Proactive 29/08/2024

Pharma & Biotech

GSK shares higher after Delaware Zantac ruling

By Proactive 28/08/2024

Pharma & Biotech

GSK gets fast-track approval from FDA for Chinese lung cancer drug

By Proactive 20/08/2024